Table 2.

Inclusion and Exclusion Criteria

Inclusion	Exclusion
Study type: Systematic reviews, clinical trials, cohort studies, case–control studies, quality improvement studies	Interventions: Pharmacological (chemotherapy) or procedural (radiation, surgery, ablation, embolization)
Population: Decompensated cirrhosis and hepatocellular carcinoma	Population: Metastatic disease with liver involvement, systemic diseases with hepatic involvement due to the variations in pathophysiology, disease trajectory, and symptom burden
Dates: No date limits applied	Comparator: If no comparator group in study
Interventions: Studies with palliative care or hospice intervention (what would typically be provided by a specialty palliative care provider or hospice team, such as communication regarding patient values, prognosis, understanding of disease process, in combination with symptom management and EOLC with multidisciplinary support)	Outcomes: Receipt of palliative care or hospice
Comparator: Usual or routine care
Outcomes: HRU, EOLC, PRO
Language: Published in English

HRU, healthcare resource utilization; EOLC, end-of-life care; PRO, patient-reported outcomes.